Evidence map›Paper›PMID 18457610›Full record

ReviewCurrent rheumatology reports2008

Cell death in osteoarthritis.

Marcello Del Carlo, Richard F Loeser

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 106 citations in OpenAlex.

  1. Erianin protects chondrocytes against IL-1β-induced oxidative stress and ferroptosis by activating GPX4/STING signaling in osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Identification of ferroptosis-related genes and potential drugs in osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. CYR61 as a Potential Apoptosis Biomarker in Osteoarthritis with Comorbidities.Journal of musculoskeletal & neuronal interactions · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Mitoprotective therapy prevents rapid, strain-dependent mitochondrial dysfunction after articular cartilage injury.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Death of chondrocytes in Kashin-Beck disease: Apoptosis, necrosis or necroptosis?International journal of experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marcello Del CarloDepartment of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Richard F Loeser
Wake Forest University · US

Funding

Aging and IGF-I in CartilageR01AG016697 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LOESER, RICHARD F · 2001 to 2009
$2.4M
NIA NIH HHS R01 AG16697
6 · The paper itself

Abstract

To date, most studies examining cell death during the development of osteoarthritis (OA) have focused on death of chondrocytes and have primarily examined advanced stages of the disease. Very good evidence suggests that chondrocyte death does occur at some point in the pathogenesis of OA and that it can be due to apoptosis, necrosis, or some combination of the two. Chondrocyte death can be induced by mechanical injury, loss of extracellular matrix, loss of growth factors, or excessive levels of reactive oxygen species. Although therapy specifically targeting cell death in human OA has not been reported, preclinical studies in animal models have provided early evidence that inhibition of caspases might slow OA-like changes in articular cartilage. Because of potential unwanted side effects from agents systemically inhibiting cell death, treatments specifically targeting cell death in OA will likely need to be delivered locally and in a manner that prevents systemic absorption. Inhibition of cell death in OA likely will not be a sole therapeutic target but rather a desired effect of interventions designed to reverse the catabolic-anabolic imbalance occurring in OA joint tissues.

Indexed as

AnimalsApoptosisCartilageChondrocytesDisease Models, AnimalGrowth PlateHumansNecrosisOsteoarthritisRabbits

Identifiers

PMID18457610
OpenAlexW2145545196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.